journal
MENU ▼
Read by QxMD icon Read
search

Clinical & Experimental Metastasis

journal
https://www.readbyqxmd.com/read/29139011/curing-brain-metastases
#1
EDITORIAL
Rahul Jandial
No abstract text is available yet for this article.
November 14, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/29139010/radiobiology-and-radiotherapy-of-brain-metastases
#2
Anuradha Thiagarajan, Yoshiya Yamada
Brain metastases are the most common intracranial tumors in adults, accounting for more than 50% of all such cases. The approach to and management of brain metastases have evolved significantly in recent years due to several reasons. These include advances in neurosurgical and radiotherapeutic techniques, improved systemic therapy options offering better systemic and intracranial disease control and prolongation of survival as a result of these improvements, making side-effects of proposed therapies (e.g. neurocognitive decline from whole brain radiotherapy) an important consideration...
November 14, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/29134398/micrornas-and-their-role-for-t-stage-determination-and-lymph-node-metastasis-in-early-colon-carcinoma
#3
Melanie Rammer, Gerald Webersinke, Sophie Haitchi-Petnehazy, Eva Maier, Hubert Hackl, Pornpimol Charoentong, Theodora Malli, Maria Steinmair, Andreas L Petzer, Holger Rumpold
Worldwide, colon cancer is among the most common cancer entities. Understanding the molecular background is the key to enable accurate stage determination, which is crucial to assess optimal therapy options. The search for preoperative biomarkers is ongoing. In recent years, several studies have proposed a diagnostic and prognostic role for miRNAs in cancer. Aim of this study was to evaluate miRNA expression patterns correlating with tumor stage, especially lymph node metastasis, in primary colon carcinoma tissue...
November 13, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/29063238/metabolic-advantages-and-vulnerabilities-in-brain-metastases
#4
Alexandra K Ciminera, Rahul Jandial, John Termini
Metabolic adaptations permit tumor cells to metastasize to and thrive in the brain. Brain metastases continue to present clinical challenges due to rising incidence and resistance to current treatments. Therefore, elucidating altered metabolic pathways in brain metastases may provide new therapeutic targets for the treatment of aggressive disease. Due to the high demand for glucose in the brain, increased glycolytic activity is favored for energy production. Primary tumors that undergo Warburg-like metabolic reprogramming become suited to growth in the brain microenvironment...
October 23, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/28965270/neurosurgical-management-of-brain-metastases
#5
Sherise D Ferguson, Kathryn M Wagner, Sujit S Prabhu, Mary F McAleer, Ian E McCutcheon, Raymond Sawaya
Brain metastases present a significant public health issue, affecting more than 100,000 patients per year in the U.S. and result in significant morbidity. Brain metastases can occur in a variety of clinical situations ranging from multiple brain metastases with uncontrolled systemic disease to a solitary metastasis in the setting of controlled systemic disease. Additionally, advances in genomics have broadened the opportunities for targeted treatment options and potentially more durable systemic responses. As such, the treatment of brain metastases is now more tailored and multimodal, involving systemic, radiation, and surgical therapies, often in combination...
September 30, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/28918542/current-chemotherapeutic-regimens-for-brain-metastases-treatment
#6
Joo Yeon Nam, Barbara J O'Brien
Brain metastasis is a common complication in advanced systemic cancer, with an increasing incidence. The diagnosis of brain metastasis historically portended a dismal prognosis. The successful development of effective treatments for patients with brain metastasis is complicated by the differences among cancer subtypes, the limited understanding of the underlying pathophysiology of BM, the impact of the blood-brain barrier, and other factors. There is now renewed interest in treating this often devastating complication of cancer, and in understanding the underlying mechanisms of disease in this "sanctuary" site...
September 16, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/28905151/the-role-of-the-neural-niche-in-brain-metastasis
#7
REVIEW
Reid Hoshide, Rahul Jandial
Cancers with neurologic metastasis are a burdensome affliction. As primary cancer care improves, the incidence of metastatic cancer increases as a result of prolonged survival time. Because of this, advances in the understanding of the mechanisms of metastasis are important for the development of continuing management strategies. Knowing how metastatic tumor cells engage, survive, and proliferate in the central nervous system (CNS) is an important first step in developing treatment paradigms. The neural niche is the soil of the CNS that accommodates tumor cells, is a microenvironment of cell signaling that exists between the tumor cell and the native neural cellular network...
September 13, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/28894989/collective-invasion-in-ductal-and-lobular-breast-cancer-associates-with-distant-metastasis
#8
Antoine A Khalil, Olga Ilina, Pavlo G Gritsenko, Peter Bult, Paul N Span, Peter Friedl
Breast cancer undergoes collective tissue invasion and, in experimental models, can collectively metastasize. The prevalence of collective invasion and its contribution to distant metastasis in clinical disease, however, remains poorly defined. We here scored the adipose tissue invasion of primary invasive ductal carcinoma (IDC), expressing E-cadherin, and E-cadherin negative invasive lobular carcinoma (ILC) and identified predominantly collective invasion patterns (86/86 samples) in both carcinoma types. Whereas collective invasion in IDC lesions retained adherens junctions, multicellular clusters and "Indian files" in ILC, despite the absence of adherens junctions (AJ) proteins E-cadherin and β-catenin, retained CD44 at cell-cell contacts...
September 11, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/28894976/implicating-anaesthesia-and-the-perioperative-period-in-cancer-recurrence-and-metastasis
#9
Julia A Dubowitz, Erica K Sloan, Bernhard J Riedel
Cancer, currently the leading cause of death in the population aged less than 85 years, poses a significant global disease burden and is anticipated to continue to increase in incidence in both developed and developing nations. A substantial proportion of cancers are amenable to surgery, with more than 60% of patients undergoing tumour resection. Up to 80% of patients will receive anaesthesia for diagnostic, therapeutic or palliative intervention. Alarmingly, retrospective studies have implicated surgical stress in disease progression that is predominantly characterised by metastatic disease-the primary cause of cancer-associated mortality...
September 11, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/28879620/historical-perspectives-on-the-biology-of-brain-metastasis
#10
J Dawn Waters, Reid Hoshide, Rahul Jandial
No abstract text is available yet for this article.
September 6, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/28758175/next-generation-sequencing-of-progressive-colorectal-liver-metastases-after-portal-vein-embolization
#11
Eve Simoneau, Jarred Chicoine, Sarita Negi, Ayat Salman, Anthoula Lazaris, Mazen Hassanain, Nicole Beauchemin, Stephanie Petrillo, David Valenti, Ramila Amre, Peter Metrakos
Portal vein embolization (PVE) can be required to stimulate liver regeneration before hepatectomy for colorectal liver metastasis (CRCLM), however PVE may also trigger CRCLM progression in patients initially exhibiting chemotherapy response. Using RNA-seq, we aimed to determine the molecular networks involved in metastatic progression in this context. A prospective study including all CRCLM patients undergoing PVE prior to hepatectomy was conducted. Paired biopsies of metastatic lesions were obtained prior to and after PVE and total RNA was isolated and used to prepare Illumina rRNA-depleted TruSeq stranded cDNA libraries for HiSeq 100 bp paired-end sequencing...
July 31, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/28744603/patterns-of-metastatic-progression-after-definitive-radiation-therapy-for-early-stage-and-locally-advanced-non-small-cell-lung-cancer
#12
Garrett L Jensen, Chad Tang, Kenneth R Hess, Zhongxing Liao, Daniel R Gomez
Current preclinical models of metastatic disease (particularly oligometastases) suggest that metastases appear in a hierarchical order. We attempted to identify systematic patterns of metastasis in non-small cell lung cancer (NSCLC) after radiation therapy (XRT). We analyzed 1074 patients treated from 12/21/1998 through 8/20/2012 with ≥60 Gy definitive radiation for initially non-metastatic NSCLC. Location and time of metastases were recorded. Regional nodal failure was noted, as was subsequent distal failure...
July 25, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/28730323/the-pathogenesis-diagnosis-and-management-of-metastatic-tumors-to-the-ovary-a-comprehensive-review
#13
REVIEW
Ondřej Kubeček, Jan Laco, Jiří Špaček, Jiří Petera, Jindřich Kopecký, Alena Kubečková, Stanislav Filip
Secondary tumors of the ovary account for 10-25% of all ovarian malignancies. The most common tumors that give rise to ovarian metastases include breast, colorectal, endometrial, stomach, and appendix cancer. The correct diagnosis of secondary ovarian tumors may be challenging as they are not infrequently misdiagnosed as primary ovarian cancer, particularly in the case of mucinous adenocarcinomas. The distinction from the latter is essential, as it requires different treatment. Immunohistochemistry plays an important role in distinguishing primary ovarian tumors from extra-ovarian metastases and, furthermore, may suggest the primary tumor site...
July 20, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/28699042/is-the-non-sentinel-lymph-node-compartment-the-next-site-for-melanoma-progression-from-the-sentinel-lymph-node-compartment-in-the-regional-nodal-basin
#14
Andrei Rios-Cantu, Ying Lu, Victor Melendez-Elizondo, Michael Chen, Alejandra Gutierrez-Range, Niloofar Fadaki, Suresh Thummala, Carla West-Coffee, James Cleaver, Mohammed Kashani-Sabet, Stanley P L Leong
Melanoma patients with additional positive lymph nodes in the completion lymph node dissection (CLND) following a positive sentinel lymph node (SLN) biopsy would have a poorer prognosis than patients with no additional positive lymph nodes. We hypothesize that the progression of disease from the SLN to the non-SLN compartment is orderly and is associated with the worsening of the disease status. Thus, the SLN and non-SLN compartments are biologically different in that cancer cells, in general, arrive in the SLN compartment before spreading to the non-SLN compartment...
July 11, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/28631253/portal-branch-ligation-does-not-counteract-the-inhibiting-effect-of-temsirolimus-on-extrahepatic-colorectal-metastatic-growth
#15
Sebastian Senger, Jens Sperling, Barbara Oberkircher, Martin K Schilling, Otto Kollmar, Michael D Menger, Christian Ziemann
The mTor-inhibitor temsirolimus (TEM) has potent anti-tumor activities on extrahepatic colorectal metastases. Treatment of patients with advanced disease may require portal branch ligation (PBL). While PBL can induce intrahepatic tumor growth, the effect of PBL on extrahepatic metastases under TEM treatment is unknown. Therefore, we analyzed the effects of TEM treatment on extrahepatic metastases during PBL-associated liver regeneration. GFP-transfected CT26.WT colorectal cancer cells were implanted into the dorsal skinfold chamber of BALB/c-mice...
June 19, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/28624994/expression-of-ezrin-and-moesin-in-primary-breast-carcinoma-and-matched-lymph-node-metastases
#16
M Bartova, J Hlavaty, Y Tan, C Singer, K Pohlodek, J Luha, I Walter
Ezrin, radixin, moesin (ERM) are important membrane-cytoskeletal crosslinkers and are suggested to play important role in cancer progression and metastasis. Even though ERM proteins were generally considered to be functionally redundant and the most studied was ezrin, recent studies highlight their distinct roles in metastatic process. Little information is available regarding the role of individual ERM proteins and their phosphorylated forms in human breast cancer. Our study is the first to examine expression of ezrin, moesin and their phosphorylated forms in primary breast tumors and matched lymph node metastases (LNMs) and their correlation with clinicopathological variables...
June 17, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/28593512/pipac-puts-pressure-on-peritoneal-metastases-from-pancreatic-cancer
#17
Jonathan P Sleeman
No abstract text is available yet for this article.
June 7, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/28516306/peritoneal-metastasis-from-pancreatic-cancer-treated-with-pressurized-intraperitoneal-aerosol-chemotherapy-pipac
#18
Martin Graversen, Sönke Detlefsen, Jon Kroll Bjerregaard, Per Pfeiffer, Michael Bau Mortensen
Patients with peritoneal metastasis (PM) from pancreatic cancer have a short life expectancy. Systemic combination chemotherapy leads to a median overall survival of 7-8 months. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) is a treatment alternative, where studies in patients with PM from ovarian, gastric and colorectal cancer show a high safety profile and interesting results. This case study report data on the PIPAC treatment in patients with PM from pancreatic cancer. In a standard laparoscopy, chemotherapeutics (cisplatin and doxorubicin) are nebulized within the peritoneal cavity...
May 17, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/28374139/16th-biennial-congress-of-the-metastasis-research-society
#19
(no author information available yet)
No abstract text is available yet for this article.
April 3, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/28447314/inhibition-of-the-insulin-like-growth-factor-1-receptor-potentiates-acute-effects-of-castration-in-a-rat-model-for-prostate-cancer-growth-in-bone
#20
Annika Nordstrand, Sofia Halin Bergström, Elin Thysell, Erik Bovinder-Ylitalo, Ulf H Lerner, Anders Widmark, Anders Bergh, Pernilla Wikström
Prostate cancer (PCa) patients with bone metastases are primarily treated with androgen deprivation therapy (ADT). Less pronounced ADT effects are seen in metastases than in primary tumors. To test if acute effects of ADT was enhanced by concurrent inhibition of pro-survival insulin-like growth factor 1 (IGF-1), rats were inoculated with Dunning R3327-G tumor cells into the tibial bone marrow cavity and established tumors were treated with castration in combination with IGF-1 receptor (IGF-1R) inhibitor NVP-AEW541, or by each treatment alone...
April 2017: Clinical & Experimental Metastasis
journal
journal
28855
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"